Polyarginine-Mediated Protein Delivery to Dendritic Cells Presents Antigen More Efficiently onto MHC Class I and Class II and Elicits Superior Antitumor Immunity  by Mitsui, Hiroshi et al.
Polyarginine-Mediated Protein Delivery to Dendritic
Cells Presents Antigen More Efficiently onto MHC
Class I and Class II and Elicits Superior Antitumor
Immunity
Hiroshi Mitsui1,2, Takashi Inozume1,2, Reiko Kitamura1, Naotaka Shibagaki1 and Shinji Shimada1
Protein transduction domains (PTDs) have been used increasingly to deliver reagents to a variety of cell types in
vitro and in vivo. We have previously shown that HIV TAT-PTD-containing whole protein antigens (Ags)-
transduced dendritic cells (DCs) stimulated Ag-specific CD8þ and CD4þ T cells. Although the cytotoxic T
lymphocytes (CTL) activity generated was sufficient to prevent engraftment of mice with Ag-expressing tumors,
treatment of tumor-bearing mice with TAT-PTD Ag-transduced DCs resulted in tumor regression in some
animals. Recently, several other PTDs were reported to promote higher transduction efficiencies than TAT-PTD.
To evaluate the role of individual PTDs in induction of immune responses in tumor vaccination studies, we
engineered recombinant fusion Ovalbumin (OVA) that contained three differrent PTDs, including the most
efficacious known PTD (polyarginine (R9)-PTD). Our results demonstrated that R9-PTD-containing OVA
transduced DCs most efficiently, and that transduction efficacy was closely correlated with the extent of Ag-
specific CD4þ and CD8þ T-cell activation in vitro and in vivo. Repeated vaccination with R9-PTD-OVA-
transduced DC in (OVA-expressing) tumor-bearing mice induced enhanced antitumor immunity, and elicited
complete rejection of tumors when DC was co-injected with adjuvants. This vaccination strategy may be
clinically applicable, and offers theoretical and practical advantages to those that are in current use.
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INTRODUCTION
The ultimate goal of tumor immunotherapy is to induce
strong tumor-specific T-cell-mediated immunity that can
block the growth and metastasis of malignant tumor cells in
a tumor-bearing host. Dendritic cells (DCs) are the most
potent antigen (Ag)-presenting cells of the immune system
(Guermonprez et al., 2002; Ardavin et al., 2004). Indeed,
several approaches have been used to load DCs with tumor
Ag. In most cases, the development of antitumor immunity
requires strategies capable of stimulating CD8þ cytotoxic
T lymphocytes (CTLs) and thus, effective delivery of Ag to
major histocompatibility complex (MHC) class I molecules
(Moron et al., 2004; Rosenberg et al., 2004). However, ample
evidence indicates that CD4þ helper T (Th) cells, particularly
IL-2- and IFN-gamma-producing Th1 cells, are another
critical component of an effective antitumor immune
response in eliminating cancer cells in patients (Porgador
et al., 1996; Pardoll and Topalian, 1998; Nishimura et al.,
1999; Qin and Blankenstein, 2000; Faiola et al., 2002; Wang
et al., 2002; Blankenstein and Qin, 2003; Ridgway, 2003;
Sato et al., 2003; Schuler et al., 2003; Rosenberg et al.,
2004). Therefore, it might be critical to induce strong
Ag-specific CD8þ and CD4þ T-cell responses simulta-
neously by presenting tumor Ags that contain both MHC
class I- and class II-binding peptide epitopes.
Previously, we and other groups have begun to explore the
utility of protein transduction domain (PTD)-containing Ags
as a component of DC-based cancer vaccines (Shibagaki and
Udey, 2002, 2003; Wang et al., 2002; Tanaka et al., 2003).
PTD are short stretches of positively charged amino acids that
enable peptides, proteins, oligonucleotides, and other re-
agents to efficiently enter cells (Lewin et al., 2000; Rothbard
et al., 2000; Schwarze et al., 2000; Eguchi et al., 2001; Ho
et al., 2001; Franc et al., 2003; Torchilin et al., 2003). We
have shown that TAT-PTD-containing full-length protein Ag-
transduced DCs stimulated Ag-specific CD8þ and CD4þ
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T cells and vaccinated against Ag-expressing tumors (Shiba-
gaki and Udey, 2002, 2003).
Recently, several other PTDs have been reported to
transduce various types of cells with higher efficiencies than
TAT-PTD (Wender et al., 2000; Ho et al., 2001; Jin et al.,
2001; Futai, 2002; Mai et al., 2002; Lea et al., 2003; Shen
et al., 2004). Our purposes in this study were to investigate
whether increased transduction potency of DCs with protein-
Ag was correlated with induction of greater Ag-specific
immune responses. We engineered recombinant ovalbumin
(OVA) fusion proteins (rOVAs) that contained high transduc-
tion efficiency PTDs including modified-TAT-PTD (named as
PTD) (Lea et al., 2003) as well as polyarginine-PTD (Wender
et al., 2000; Jin et al., 2001; Futai, 2002; Mai et al., 2002;
Shen et al., 2004) and compared their activities with that of
TAT-PTD-OVA.
Our results clearly demonstrated that nonarginine (R9)-
PTD showed the highest transduction efficiency among the
PTDs studied, and that vaccination with R9-PTD-transduced
DCs in vivo elicited superior antitumor effects by inducing
greater CD8þ and CD4þ T-cell activation and enhanced
boosting effects after second immunization, resulting in
complete rejection of tumors co-vaccinated with OK432 that
has been applied clinically as adjuvants. These results suggest
that success in cancer immunotherapy may require strong
Th-induction in immunosuppressive environment.
RESULTS
Production and characterization of recombinant
PTD-containing OVA proteins
Preliminary studies demonstrated that there was little
difference in DC transduction efficiencies when rOVA
constructs containing TAT-PTD and modified-TAT (named
as PTD)-PTD were utilized (data not shown). A construct
encoding a tandem PTD (PTDx2)-containing OVA was
engineered by inserting two PTD fragments in tandem and
investigated. Figure 1 shows amino-acid sequences of each
PTD we studied, and schematized rPTD-containing and
control OVA proteins. Characterization of purified proteins
by SDS-PAGE revealed predominantly single species with
appropriate sizes (Figure S1).
Distribution of rOVAs in DCs
Previously, we demonstrated that rTAT-PTD-containing OVA
(TAT-HA-OVA) could transduce bone-marrow-derived DCs
(Shibagaki and Udey, 2002). To assess accumulation of the
rOVA fusion proteins containing other PTDs, DC treated with
rOVAs were stained with mAb against the hemagglutinin
(HA) epitope. HA-OVA localized in a discrete compartment
(Figure 2a, Figure S2), as reported previously (Shibagaki and
Udey, 2002). In contrast, although rPTD-containing OVAs
accumulated in cells focally as endocytotic vesicles in the
early phase (Figure S2), these were also distributed more
diffusely (Figure 2a), especially in R9-HA-OVA-treated DCs.
Figure 2b shows the average fluorescence intensities
of rOVA-treated DCs. These results demonstrated the
higher ability of R9-PTD-containing proteins to be transduced
into DCs.
Formation of MHC class I: peptide epitopes following
rOVA-transduction of DCs
By quantifying cell surface levels of H-2Kb:SIINFEKL com-
plexes with mAb 25.D1.16 after exposure of DCs to rPTD-
containing OVAs at various concentrations and for various
periods of time, we determined that MHC class I loading was
near maximal when DCs were incubated with 300 nM each
rPTD-containing OVA for 18 hours (data not shown). Our
preliminary data also demonstrated that treatment of DCs
with more than 3 mM rPTD-containing OVAs affected the cell
viability. Although incubation of DCs with HA-OVA did not
result in the formation of detectable H-2Kb:SIINFEKL com-
plexes on their surface; incubation with rPTD-containing-
OVA proteins resulted in the formation of detectable
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Figure 1. Amino-acid sequences of PTDs studied and schematic
representation of rOVAs.
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Figure 2. (a) Distribution of rOVAs in DC. DC were incubated with rOVAs
(300 nM each) for 5 hours, washed, fixed, permiabilized, stained with anti-HA
mAb and Cy3-conjugated anti-mouse IgG, and analyzed via confocal laser
microscopy. (b) Comparison of fluorescence intensity of each rOVA-treated
DC. Average cell intensity of three cells was digitally analyzed with Adobe
Photoshop software. The data shown are representative in three individual
experiments.
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complexes (Figure 3a, Figure S3), correlating with the
transduction efficiencies seen in Figure 2.
Priming of cytotoxic lymphocytes after administration
of rOVA-transduced DCs
Next, we compared the ability of rPTD-containing-OVA-
transduced DCs to stimulate naive CTL precursors in vivo.
DCs were incubated with SIINFEKL peptide or rOVA
constructs and administered intradermally to naive mice
and CTL activity was measured. Administration of SIINFEKL-
treated and rPTD-containing-OVA-treated DCs to naive mice
primed CTL that killed SIINFEKL-pulsed EL-4 and EG.7 targets
(Figure 3b), but not EL-4 cells (data not shown). The CTL
responses in the PTDx2-, and R9-HA-OVA-transduced DC-
immunized mice were much higher than those in the
peptide-DC-, or TAT-HA-OVA-DC-immunized mice with
EG.7 targets. The responses induced by HA-OVA-treated
DCs were only slightly above background.
Activation of CD4þ T cells by rPTD-OVA-transduced DCs
We previously demonstrated that TAT-HA-OVA was also
processed and presented to CD4þ T cells by transduced DCs
(Shibagaki and Udey, 2002). To test this potential by other
PTD-containing rOVAs, CD4þ T cells were prepared from
mice that had been immunized with native OVA in adjuvant
and then restimulated in vitro with DCs that had been
pretreated with native OVA, rOVAs, or SIINFEKL peptide.
DCs treated with SIINFEKL peptide did not activate T cells to
a greater extent than untreated DCs, or R9-PTD-containing
irrelevant protein (R9-HA-LACK) (Figure 4). DCs that had
been loaded with native OVA, HA-OVA, TAT-HA-OVA, and
PTDx2-HA-OVA were equipotent with regard to their ability
to stimulate thymidine incorporation into OVA-primed
CD4þ T cells. Interestingly, R9-HA-OVA-transduced DCs
elicited B3-fold greater CD4þ T-cell activation than other
OVA-treated DCs. Expression levels of MHC class II, CD86,
CD40 on each rOVA-treated, or untreated DCs were almost
identical (Figure S4). These results indicated that, consistent
with the immunofluorescence images in Figure 2a, R9-HA-
OVA is more effectively endocytosed than the other fusion
proteins, resulting in more Ag-presentation via MHC class II
molecules.
Treatment of EG.7-bearing animals with rPTD-OVA-transduced
DCs
Our results indicated that treatment with R9-HA-OVA-
transduced DCs could induce potent immune responses
by activating Ag-specific CD8þ and CD4þ T cells
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Figure 3. Expression of SIINFEKL-epitope and induction of CTLs by rOVA-
transduced DC. (a) DC were incubated with rOVAs (300 nM for 18 hours) or
SIINFEKL-peptide (10 mM for 1 hour), and surface levels of H-2Kb:SIINFEKL
complexes on CD11cþ cells were assessed using flow cytometory with
25.D1.16 mAb. DMFI¼mean fluorescence intensity of 25.D1.16mean
fluorescence intensity of isotype control mAb. The data shown is
representative in three individual experiments. (b) Mice were immunized
with DC that had been treated with rOVAs (300 nM for 18 hours) or
SIINFEKL-peptide (10 mM for 1 hour) (5105 cells injected intradermally).
After 10 days, lymph node and spleen cells were restimulated in vitro with
mitomycin-C-treated EG.7 cells and CTL reactivity with SIINFEKL-pulsed EL4
or EG.7 cells was determined using calcein-release assay. CTL reactivities
with EL-4 cells were o3% (data not shown).
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Figure 4. OVA-specific stimulation of CD4þ T cells by Ag-transduced DC.
CD4þ T cells from popliteal lymph nodes of mice primed with native OVA
protein in CFA were co-cultured with DC that had been treated with native
OVA, rOVAs, or R9-PTD-containing recombinant irrelevant protein
(R9-HA-LACK) (300 nM for 18 hours), or SIINFEKL-peptide (10 mM for 1 hour),
for 72 hours. Cell proliferation was determined by measurement of
[3H]-methylthymidine incorporation. The data shown are representative in
three individual experiments.
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simultaneously in vivo. Then we investigated the antitumor
effects in treatment protocols, as even TAT-HA-OVA-trans-
duced DCs could completely prevent EG.7 growth in tumor
protection studies (Shibagaki and Udey, 2002). Our previous
and preliminary data showed that multiple immunizations
with rPTD-containing Ag-transduced DCs, but not peptide-
treated DCs, were more effective than single immunizations.
Therefore, naive mice were injected subcutis with EG.7 cells
(at day 0) and subsequently immunized twice at weekly
intervals (days 3 and 10) with DCs that had been incubated
with SIINFEKL peptide, or rOVAs as indicated. Tumors grew
progressively in mice immunized with DCs or HA-OVA-
transduced DCs (Figure 5a). Tumor growth was suppressed by
treatment with SIINFEKL-pulsed DCs, but none of the EG.7-
bearing mice could reject tumor completely. In contrast,
tumor growth was stopped transiently after second immuni-
zation by treatment with each rPTD-containing-OVA-trans-
duced DCs. These boosting effects after second immunization
were observed predominantly in mice treated with R9-HA-
OVA-transduced DCs, resulting in higher antitumor effects
after that period. Table 1 summarizes our experiments in
three therapeutic vaccination studies.
To determine whether there was a relationship between
the ability of the DC-based vaccine to elicit CTL responses
and antitumor immunity, spleen cells were recovered from
individual animals in Figure 5a on day 22, and restimulated
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Figure 5. Treatment of EG.7-bearing mice with rOVA-transduced DC. (a) C57BL/6 naive mice (5 per group) were inoculated in the subcutis with 1106
EG.7 cells on day 0 and subsequently immunized in the opposite flank with DC that had been incubated with rOVAs or SIINFEKL-peptide (5105 cells injected
on days 3 and 10). Tumor indices (in millimeters) were assessed twice weekly. Data are presented as average7SD per group and are representative of one
of three experiments. Tumor index (in mm)¼ square root (lengthwidth) of tumor nodule. R9-HA-OVA-DC group is different from SIINFEKL-DC, or
TAT-HA-OVA-DC group on days 14 and 22, Po0.05. (b) CTL reactivities with EG.7 cells were inversely correlated with tumor burdens in individual mouse.
Splenocytes from individual EG.7-bearing mice (five per group) in were harvested on day 22, restimulated with mitomycin-C-treated EG.7 cells and CTL
reactivities with EG.7 cells (effector:target ratio¼33) were determined by calcein-release assays. (c) Comparison of the levels of anti-OVA antibodies in
individual mice. To detect the anti-OVA IgG Ab in mouse serum on day 22, ELISA assay was performed with native OVA-coated plates. Sera from naive mice
were used as negative control. (d) Well correlation between CTL activities and Ab production levels in individual mice treated with PTD-containing
OVA-transduced DC. Relationship between CTL activities shown in (b) and Ab production levels in (c) were also analyzed. r¼ 0.60 (TAT-HA-OVA-DC),
0.92 (PTDx2-HA-OVA-DC), 0.82 (R9-HA-OVA-DC), and 0.26 (SIINFEKL-DC). Plots within dot-line indicate the tumor-free (rejecting) mice.
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with EG.7 cells, and their ability to lyse EG.7 targets was
assessed. As shown in Figure 5b, a strong, inverse correlation
between CTL activity and tumor burden was observed
independently of which vaccine had been used to treat
tumor-bearing mice.
To gain insight into CD4þ T-cell-dependent responses
during the course of the treatment study, we also compared
the production of (polyclonal) anti-OVA antibodies from
individuals on day 22. The levels of anti-OVA IgG in mice
immunized with R9-HA-OVA-transduced DCs were rela-
tively higher than the others (Figure 5c), consistent with
greater Ag-specific CD4þ T-cell activation. Interestingly, a
strong correlation between CTL activity and antibody
production was also observed independently in each group
treated with PTD-containing OVA-transduced DCs (Figure
5d).
Complete rejection of EG.7 tumor with R9-PTD-OVA-
transduced DCs and adjuvants
Our present data demonstrated that the treatment of tumor-
bearing mice by repeated immunization with R9-HA-OVA-
transduced DCs induced superior antitumor effects than
others. However, we could not achieve complete rejections
of all tumor-bearing mice with this strategy (Table 1). It has
been reported that antitumor effects of DCs vaccine can be
augmented with peritumoral injections of streptococcal
preparation OK432 via the induction of Th1-type cytokines
(Tamada et al., 1998). We investigated the antitumor effects
of DC vaccines in conjunction with co-injection of adjuvants
(OK432 or LPS) simultaneously in the same protocol. Co-
injections of adjuvants with HA-OVA-treated DC group
(Figure 6a) had minimal activities. In contrast, almost all of
tumor-bearing mice rejected EG.7 completely after a second
treatment with R9-HA-OVA-transduced DCs when adjuvants
were co-injected. We also analyzed CTL activities against
EG.7 and levels of anti-OVA Ab from mice in Figure 6a. As
shown in Figure 6b, the CTL activities in HA-OVA-treated DC
mice were only slightly above background and were not
increased by adjuvants, whereas levels of anti-OVA Ab were
higher after co-injection of adjuvants. Interestingly, although
there were no significant differences in CTL activities and
levels of anti-OVA Ab among tumor-free mice in the R9-HA-
OVA-treated DC groups on average, co-administration of
OK432 appeared to potentiate OVA-specific immune re-
sponses. Table 2 summarizes our experiments in three
therapeutic vaccination studies with co-injection of OK432.
Tumor growth was further suppressed by OK432 in SIINFEKL-
DC group, but antitumor effects were still inferior to those in
R9-HA-OVA-treated DC group. These results indicated that
co-injection of adjuvants might modify the (immunosuppre-
ssive) environment of tumor-bearing hosts and result in the
induction of optimal immune responses.
Table 1. Summary of tumor-free survival and tumor
burden after vaccination with protein Ag-transduced
DCs
Group Immunogen
Tumor-free
mice
Tumor
burden
A None 0/10 26.0670.94
B DC (2 ) 0/15 26.1772.68
C SIINFEKL-DC (2 ) 0/15 20.2572.92
D HA-OVA-DC (2 ) 0/15 28.0672.45
E TAT-HA-OVA-DC (2 ) 0/15 18.0875.17
F PTDx2-HA-OVA-DC (2 ) 2/15 (13.3%) 15.3577.44
G R9-HA-OVA-DC (2 ) 7/15 (46.7%) 8.6378.77
DC, dendritic cell; OVA, ovalbumin; PTD, protein transduction domain.
Data from three individual treatment studies (using the same protocol as
described in Figure 5) were pooled (days 22–24 data reported). Tumor
burdens represent the average tumor indices (square root of the product of
horizontal and vertical dimensions) in millimeters.
G is different from B (Po6.7 107), C (Po8.2 105), D
(Po1.3 106), E (P=0.0014), F (P=0.051) using Student’s t-test.
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Figure 6. Treatment of EG.7-bearing mice with rOVA-transduced DC and
adjuvants. (a) C57BL/6 naive mice (five per group) were injected subcutis
with 1 106 EG.7 cells on day 0 and subsequently immunized with DC that
had been incubated with rOVAs on days 3 and 10. OK432 (0.25 KE/day/mice)
or LPS (100mg/day/mice) were co-injected on days 3, 4, 5, and day 10, 11, 12.
Tumor sizes were assessed twice weekly. Each line in a given panel represents
one individual mouse. The data shown is representative of three individual
experiments. (b) Effects by co-injection of adjuvants on CTL activities and
production of antibodies. Tumor-challenged individual mice in Figure 6a on
day 25 were analyzed. Dots inside the boxed area indicate the tumor-free
(rejecting) mice.
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DISCUSSION
Results described here demonstrated that R9-PTD, known as
the most efficacious PTD (Wender et al., 2000), induced
more efficient protein transduction of DC than the other PTDs
studied, resulting in the efficient induction of Ag-specific
immune responses mediated by CD8þ and CD4þ T cells,
and in a superior antitumor effects. Recently, the pathway for
polyarginine entry into mammalian cells has been elucidated
(Fuchs and Raines, 2004). R9-PTD-mediated delivery of
molecules into live mammalian cells involved: (i) binding to
cell surface heparan sulfate, (ii) uptake by endocytosis, (iii)
release upon heparan sulfate degradation, and (iv) leakage
from endocytic vesicles (into the cytosol) depending upon
PTD concentrations and peptide:lipid ratios. This scenario
predicted indicated that there are at least two major steps that
regulate the efficacy of Ag delivery to cytosol by PTDs. One is
endocytosis and the other is leakage efficiency. Although the
exact mechanisms for internalization and processing of PTD-
containing protein Ag by DCs has not yet been revealed, our
data indicated that R9-PTD-mediated Ag delivery to DCs
should facilitate efficient cross-presentation.
Our previous and present data demonstrated that although
SIINFEKL peptide-pulsed DCs could induce epitope-specific
CTL (Shibagaki and Udey, 2002), boosting did not augment
immune responses. In contrast, multiple vaccinations with
rPTD-containing Ag-transduced DCs did enhance antitumor
effects (Figure 5a), and these effects correlated with the
potency of Ag-specific CD4þ T-cell activation in vitro
(Figure 4). Thus, induction of strong immune responses
mediated by Th cells might be another key factor promoting
better antitumor effects in vivo. It is also possible that rPTD-
containing Ag-transduced DCs elicited higher avidity CTL
than peptide-pulsed DCs, and that high avidity cells
expanded more vigorously in vivo after a second exposure
to Ag (Zeh et al., 1999).
The variation of antitumor effects elicited by DC vaccines,
even in the same group (Figure 5), is of interest. It is well
known that the environment in tumor-bearing hosts is
actively immunosuppressive. It is tempting to implicate
immunoregulatory T cells , especially CD4þCD25þ T cells
and natural killer T cells, in the negative regulation of
antitumor immunity (Terabe and Berzofsky, 2004; Antony
et al., 2005), especially within and surrounding tumors (Yu
et al., 2005). Moreover, several studies reported defective
function of DCs in tumor-bearing hosts with advanced-stage
disease (Almand et al., 2000; Kiertscher et al., 2000;
Gabrilovich, 2004). Success in cancer immunotherapy
requires circumvention of immunosuppression in tumor-
bearing hosts and induction of optimal immune responses
to tumors. Accumulating results suggest that co-injections of
vaccination with adjuvants in vivo can enhance vaccination
effects by activating innate immunity (Okamoto et al., 1997;
Tatsugami et al., 2000; Mashino et al., 2002; Nakahara et al.,
2003; Okamoto et al., 2004), or by blocking of suppressive
effect by CD4þCD25þ immunoregulatory T cells (Pasare
and Medzhitov, 2004; Yang et al., 2004). Our results
demonstrated that complete rejection of tumors were
observed in all mice co-injected with OK432 or LPS and
R9-HA-OVA-treated DCs (Figure 6, Table 2), indicating the
importance of innate signals for DCs as well as Ag-specific Th
cell activation for the optimal immune responses in
immunosuppressive environments. For this reason, our
vaccination strategy using R9-PTD as Ag-delivery to DCs
may have an advantage in induction of higher Th-cell
activation than natural Ag-delivery.
The DC protein-transduction approach described here is
also attractive for several additional reasons. Production of
bacterial recombinant candidate tumor Ag is relatively
straightforward, requiring only knowledge of the nucleotide
sequence and predicted hydrophobicity. As compared with
administration of peptide-pulsed DC, MHC class I alleles and
class I binding peptides need not be defined before
vaccination with protein-transduced DC. In addition, the
number of epitopes recognized by CTL in recipients of
protein-transduced DC should be greater than that achievable
with peptide-pulsed DC. Finally, the use of proteins rather
than plasmids or viral vectors for transduction avoids
practical and theoretical safety concerns regarding the
potential for genomic modification or generation of replica-
tion-competent viruses via recombination.
Thus, this approach could be clinically applicable, and
offers theoretical and practical advantages to those that are in
current use, such as peptide therapy.
MATERIALS AND METHODS
Generation and characterization of recombinant protein Ags
His6-tagged TAT-hemagglutinin (HA)-OVA (TAT-HA-OVA) and HA-
OVA constructs were generated as previously described (Shibagaki
and Udey, 2002). Constructs encoding His6-tagged PTD-HA-OVA
(PTD-HA-OVA) or His6-tagged R9-HA-OVA were engineered by
insertions of synthesized annealed double-stranded oligodeoxy-
nucleotides encoding each PTD sequence (Figure 1) in frame into
the pHA-OVA plasmid digested by BamHI. PTD-tandem (PTDx2)-
HA-OVA was engineered by double-insertion of double-stranded
oligodeoxynucleotides of PTD into the pHA-OVA plasmid. High
expression BL21 (DE3) (Novagen, Madison, WI) transformants were
selected after blotting lysates of transformants with anti-HA mAb
Table 2. Summary of tumor-free survival and tumor
burden after vaccination with OVA Ag-treated DCs
plus co-injection of OK432
Group Immunogen
Tumor-free
mice
Tumor
burden
A DC (2 ) 0/10 26.6972.50
B DC+OK432 (2 ) 0/15 19.6873.74
C SIINFEKL-DC+OK432 (2 ) 4/15 (26.7%) 10.3176.95
D HA-OVA-DC+OK432 (2 ) 3/15 (20%) 14.6778.10
E R9-HA-OVA-DC+OK432 (2 ) 15/15 (100%) 0
DC, dendritic cell; OVA, ovalbumin.
Data from three individual treatment studies (using the same protocol as
described in Figure 6) were pooled (days 20–22 data reported). Tumor
burdens represent the average tumor indices (square root of the product of
horizontal and vertical dimensions) in millimeters.
E is different from B (Po2.41013), C (Po2.5105), D
(Po3.0 106) using Student’st-test.
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(Covance, Richmond, CA). Denatured recombinant OVAs (rOVAs)
were purified by sequential Ni2þ NTA-agarose chromatography, fast
protein liquid ion-exchange chromatography, and gel filtration
chromatography as described (Vocero-Akbani et al., 2000). Proteins
were stored at 701C in PBS/10% glycerol and thawed immediately
before use. SDS-PAGE was performed with NuPAGE 4–12% Bis-Tris
gels and morpholinopropane sulphonic acid running buffer (Invitro-
gen Japan, Tokyo, Japan). Endotoxin contamination of recombinant
proteins was determined via Limulus lysate assay (BioWhittaker,
Walkersville, MD). Recombinant proteins were treated with poly-
myxin B sulfate (50 mg/ml; Sigma-Aldrich, St Louis, MO) before
addition to DCs (Shibagaki and Udey, 2002).
Mice, DCs and tumor cells
Six- to 8-week-old female C57BL/6 mice were purchased from SLC
Japan (Hamamatsu, Japan). All animal experiments were approved
by the Institutional Review Boarded at University of Yamanashi,
Faculty of Medicine. DCs were obtained by culturing C57BL/6 bone
marrow cells in RPMI 1640 containing 5% fetal bovine serum,
glutamine, penicillin/streptomycin (Invitrogen), murine rGM-CSF,
and rIL-4 (10 ng/ml each; PeproTech, Rocky Hill, NJ) for 5 days. After
enrichment on 14.5% metrizamide gradients and an overnight
incubation, nonadherent and loosely adherent cells were harvested
and used in experiments. EL-4 cells were purchased from the
American Type Culture Collection (Manassas, VA) and OVA cDNA
stable-transfectants (EG.7 cells) were provided by M. Bevan
(University of Washington, Seattle, WA). Cell lines were cultivated
in RPMI 1640 containing 10% fetal bovine serum, glutamine, and
penicillin/streptomycin.
Confocal laser microscopy
After incubation with rOVAs (300 nM for 5 hours), DCs were washed
twice with PBS, fixed with 4% paraformaldehyde in PBS, permea-
bilized with 0.2% NP-40, blocked with 5% goat serum, and stained
with 5 mg/ml anti-HA mAb (Covance, Berkeley, CA) and Cy3-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch Labora-
tories, West Grove, PA). Stained cells were analyzed using a
fluorescence microscope/laser scanning confocal microscope (Leitz
DMRBF and Leica TCS4D; Leica, Germany). Digital images were
further analyzed with Adobe Photoshop software (Adobe Systems,
Mountain View, CA).
Flow cytometry
25.D1.16 mAb reactive with SIINFEKL:H-2Kb complexes (Porgador
et al., 1997) was obtained from R. Germain (National Institute of
Allergy and Infectious Disease, Bethesda, MD). Mouse IgG1 (isotype
control), anti-CD16/CD32 (2.4G2), PE-conjugated goat anti-mouse
IgG was purchased from BD Pharmingen (San Diego, CA). Cells
were stained for surface Ag expression and analyzed using a
FACScan flow cytometer equipped with CellQuest software (BD
Biosciences, Mountain View, CA). DC FcR was blocked with anti-
CD16/CD32 before staining.
Reagents
NH2-SIINFEKL-COOH peptide (Rotzschke et al., 1991) was
purchased from Qiagen. Native OVA protein and LPS were
purchased from Sigma-Aldrich. Streptococcal preparation OK432
(Picibanil), which has been applied clinically against various types of
cancers as adjuvants, was purchased from Chugai Pharmaceutical
Co. (Tokyo, Japan). FM1-43 FX, which stains plasma membranes and
endocytotic vesicles (Cochilla et al., 1999; Fuchs and Raines, 2004),
was purchased from Molecular Probes, Inc. (Eugene, OR).
Quantification of CTL
Mice were immunized intradermally in the right flank with 5 105
DCs that had been treated with SIINFEKL peptide (10mM for 1 hour),
with rOVA (300 nM for 18 hours) on day 0. On day 10, splenocytes
and lymph node cells were harvested and restimulated in vitro with
mitomycin-C-pretreated (50 mg/ml for 45 minutes) SIINFEKL-pulsed
EL-4 or EG.7 cells for 5 days. CTL activity was assessed on day 15
using calcein-release assays performed as previously described
(Shibagaki and Udey, 2002, 2003). Nonadherent spleen and lymph
node cells were harvested from in vitro restimulation cultures and
used as effector cells. EL-4, SIINFEKL-pulsed EL-4, and EG.7 cells
were labeled with calcein (Molecular Probes, Eugene, OR), washed
and added to 96-well round-bottom microtiterplates with various
numbers of effector cells. Plates were incubated for 2.5 hours,
supernatants were recovered and calcein-release was measured
using a Powerscan HT multidetection microplate reader (Dainippon
Pharmaceutical Co; Tokyo, Japan). Percent-specific lysis¼
(experimentalspontaneous/maximalspontaneous) 100. Maximal
lysis was achieved with 0.1% Triton X-100.
CD4þ T-cell proliferation assay
Primed CD4þ T cells were elicited in naive mice by injecting
footpads with 50 mg of native OVA protein in 30 ml of complete
Freund’s adjuvant (Invitrogen) on day 0. On day 10, popliteal lymph
node cells were harvested and CD4þ T cells were isolated (490%
purity) using mouse CD4 cell enrichment columns (R&D Systems,
Minneapolis, MN). CD4þ T cells were subsequently cocultured in
96-well flat-bottom microtiter plates (3 105/well) with varying
numbers of DCs that had been pretreated with SIINFEKL peptide
(10 mM for 1 hour), native OVA, or rOVAs (300 nM for 18 hours each).
[3H]-methylthymidine (Amersham Pharmacia Biotech; Piscataway,
NJ) was added for the final 16 hours of a 72-hour incubation period
and cell-associated radioactivity was measured by direct beta
counting.
Tumor treatment study
In tumor treatment studies, EG.7 cells (1 106) were injected into
the subcutis of naive mice on day 0 followed by two weekly
injections of DCs (5 105 per mice) into the opposite flanks on days
3 and 10. Tumor sizes were determined by palpation biweekly in a
blinded fashion. Tumor index (in millimeters)¼ square root
(lengthwidth). Between days 22 and 25, EG.7-reactive CTL
activity was quantified after in vitro restimulation of RBC-depleted
spleen cells with mitomycin C-treated EG.7 cells. In some
experiments, OK432 (0.25 KE/mouse/day) or LPS (10 mg/mouse/
day) was co-injected into the peri-tumoral site on days 3, 4, 5, and
days 10, 11, 12, respectively.
ELISA assay for detection of anti-OVA antibodies
Between days 22 and 25 in tumor treatment studies, sera from
individual mice were collected just before killing. To determine
levels of anti-OVA IgG in mouse sera, 96-well flat-bottom
microtiterplates were coated with 5 mg/ml of native OVA in 50 mM
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Tris-HCl (pH 9.5) for 2 hours, blocked with 1 mg/ml of skim milk in
PBS/1 mM EDTA for 2 hours, and serum samples were added to the
wells for 2 hours. HRP-conjugated anti-mouse IgG Ab (Jackson
ImmunoResearch) and a TMB substrate kit (Pierce; Rockford, IL)
were used for detection. Absorbance at 450 nm was measured with a
Powerscan HT multidetection microplate reader.
Statistical analysis
Differences between the means of experimental groups were
analyzed using the Student’s t-test. Differences were considered
significant when Po0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. Coomassie blue-stained 4–12% SDS-PAGE gels in which
Ni-affinity- and ion exchange chromatography-purified HA-OVA (A),
TAT-HA-OVA (B), PTDx2-HA-OVA (C), and R9-HA-OVA (D) were resolved.
Figure S2. Colocalization of rOVAs with endocytotic vesicles in DC.
Figure S3. Expression of H-2Kb:SIINFEKL complexes by rOVA-treated DC.
Figure S4. Expression of I-Ab, CD86, or CD40 on each rOVA-treated DC after
18 h cultivation.
REFERENCES
Almand B, Resser JR, Lindman B, Nadaf S, Clark JL, Kwon ED et al. (2000)
Clinical significance of defective dendritic cell differentiation in cancer.
Clin Cancer Res 6:1755–66
Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR
et al. (2005) CD8+ T cell immunity against a tumor/self-antigen is
augmented by CD4+ T helper cells and hindered by naturally occurring T
regulatory cells. J Immunol 174:2591–601
Ardavin C, Amigorena S, Reise Sousa C (2004) Dendritic cells: immuno-
biology and cancer immunotherapy. Immunity 20:17–23
Blankenstein T, Qin Z (2003) The role of IFN-g in tumor transplantation
immunity and inhibition of chemical carcinogenesis. Curr Opin
Immunol 15:148–54
Cochilla AJ, Angleson JK, Betz WJ (1999) Monitoring secretory membrane
with FM1-43 fluorescence. Annu Rev Neurosci 22:1–10
Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H et al. (2001)
Protein transduction domain of HIV-TAT protein promotes efficient
delivery of DNA into mammalian cells. J Biol Chem 276:26204–10
Faiola B, Doyle C, Gilboa E, Nair S (2002) Influence of CD4+ T cells and the
source of major histocompatibility complex class II-restricted peptides
on cytotoxic T cell priming by dendritic cells. Immunology 105:47–55
Franc BL, Mandl SJ, Siprashvill Z, Wender P, Contag CH (2003) Breaching
biological barriers: protein transduction domains as tools for molecular
imaging and therapy. Mol Imaging 4:313–23
Fuchs SM, Raines RT (2004) Pathway for polyarginine entry into mammalian
cells. Biochemistry 43:2438–44
Futai S (2002) Arginine-rich peptides potential for intracellular delivery of
macromolecules and the mystery of the translocation mechanisms. Int J
Pharmaceu 245:1–7
Gabrilovich D (2004) Mechanisms and functional significance of tumor-
induced dendritic cell defects. Nat Rev Immunol 4:941–52
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002)
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev
Immunol 20:621–67
Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF (2001) Synthetic
protein transduction domains: enhanced transduction potential in vitro
and in vivo. Cancer Res 61:474–7
Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, Han KH et al. (2001)
Transduction of human catalase mediated by an HIV-1 TAT protein basic
domain and arginine-rich peptides into mammalian cells. Free Radical
Biol Med 31:1509–19
Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumors promote altered
maturation and early apoptosis of monocyte-derived dendritic cells.
J Immunol 164:1269–76
Lea NC, Buggins AGS, Orr SJ, Mufti GJ, Thomas SB (2003) High efficiency
protein transduction of quiescent and proliferating primary hematopoie-
tic cells. J Biochem Biophys Methods 55:251–8
Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT et al. (2000)
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking
and recovery of progenitor cells. Nat Biotechnol 18:410–4
Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD (2002) Efficiency of
protein transduction is cell type-dependeny and is enhanced by dextran
sulfate. J Biol Chem 277:30208–18
Mashino K, Sadanaga N, Tanaka F, Ohta M, Yamaguchi H, Mori M (2002)
Effective strategy of dendritic cell-based immunotherapy for advanced
tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol
Cancer Therapeu 1:785–94
Moron G, Dadaglio G, Leclerc C (2004) New tools for antigen delivery to the
MHC class I pathway. Trend Immunol 25:92–7
Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H (2003) Dendritic cells
stimulated with a bacterial product, OK-432, efficiently induce cytotoxic
T lymphocytes specific to tumor rejection peptide. Cancer Res
63:4112–8
Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M et al.
(1999) Distinct role of antigen-specific T helper type 1(Th1) and Th2 cells
in tumor eradication in vivo. J Exp Med 190:617–27
Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU et al.
(2004) Expression of Toll-like receptor 4 on dendritic cells is significant
for anticancer effect of dendritic cells-based immunotherapy in
combination with an active component of OK-432, a streptococcal
preparation. Cancer Res 64:5461–70
Okamoto T, Harada M, Tamada K, Yoshida H, Ito O, Kong YY et al. (1997)
Local injection of OK432 can augment the Th1-type T cell response in
tumor-draining lymph node cells and increase their immunotherapeu-
tical potential. Int J Cancer 70:598–605
Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in
antitumor immunity. Curr Opin Immunol 10:588–94
Pasare C, Medzhitov R (2004) Toll-dependent control mechanisms of CD4T
cell activation. Immunity 21:733–41
Porgador A, Snyder D, Gilboa E (1996) Induction of antitumor immunity using
bone marrow-generated dendritic cells. J Immunol 156:2918–26
Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN (1997)
Localization, quantitation, and in situ detection of specific peptide-
MHC class I complexes using a monoclonal antibody. Immunity
6:715–26
Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves
inhibition of angiogenesis that is dependent on IFN gamma receptor
expression by nonhematopoietic cells. Immunity 12:677–86
Ridgway D (2003) The first 1000 dendritic cell vaccines. Cancer Invest
21:873–86
Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving
beyond current vaccines. Nat Med 10:909–15
Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PI et al.
(2000) Conjugation of arginine oligomers to cyclosporin A facilitates
topical delivery and inhibition of inflammation. Nat Med 11:1253–7
Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG (1991)
Exact prediction of a natural T cell epitope. Eur J Immunol 11:2891–4
Sato M, Chamoto K, Nishimura T (2003) A novel tumor-vaccine cell therapy
using bone marrow-derived dendritic cell type 1 and antigen-specific
Th1 cells. Int Immunol 15:837–43
www.jidonline.org 1811
H Mitsui et al.
Polyarginine PTD-Mediated Ag Delivery to DCs
Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells
in cancer immunotherapy. Curr Opin Immunol 15:138–47
Schwarze SR, Hruska KA, Dowdy SF (2000) Protein transduction: unrestricted
delivery into all cells? Trends Cell Biol 10:290–5
Shen H, Mai JC, Qiu L, Cao S, Robbins PD, Cheng T (2004) Evaluation of
peptide-mediated transduction in human CD34+ cells. Hum Gene Ther
4:415–9
Shibagaki N, Udey MC (2002) Dendritic cells transduced with protein
antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
J Immunol 168:2393–401
Shibagaki N, Udey MC (2003) Dendritic cells transduced with TAT protein
transduction domain-containing tyrosinase-related protein 2 vaccinate
against murine melanoma. Eur J Immunol 33:850–60
Tamada K, Harada M, Abe K, Li T, Tada H, Onoe Y et al. (1998) Antitumor
vaccination effect of dendritic cells can be augmented by locally
utilizing Th1-type cytokines from OK432-reactive CD4+ T cells. Cancer
Immunol Immunother 46:128–36
Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS (2003)
Induction of antigen-specific CTL by recombinant HIV trans-activating
fusion protein-pulsed human monocyte-derived dendritic cells.
J Immunol 170:1291–8
Tatsugami K, Tamada K, Abe K, Harada M, Nomoto K (2000) Local injections
of OK432 can help the infiltration of adoptively transferred CD8+ T
cells into the tumor sites and synergistically induce the local production
of Th1-type cytokines and CXC3 chemokines. Cancer Immunol
Immunother 49:361–8
Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity.
Curr Opin Immunol 16:157–62
Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjoppoulos-
Sternberg B, D’Souza GG (2003) Cell transfection in vitro and in vivo
with nontoxic TAT peptide–liposome–DNA complexes. Proc Natl Acad
Sci USA 100:1972–7
Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent toll-like receptor
signals are required for reversal of regulatory T cell-mediated CD8
tolerance. Nat Immunol 5:508–15
Yu P, Lee Y, Liy W, Krausz T, Chong A, Schreiber H et al. (2005) Intratumor
depletion of CD4+ cells unmasks tumor immunogenicity leading to the
rejection of late-stage tumors. J Exp Med 201:779–89
Vocero-Akbani A, Lissy NA, Dowdy SF (2000) Transduction of full-length TAT
proteins directly into mammalian cells: analysis of T cell receptor
activation-induced cell death. Methods Enzymol 322:508–21
Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC et al. (2002)
Induction of CD4+ T cell-dependent antitumor immunity by TAT-
mediated tumor antigen delivery into dendritic cells. J Clin Invest
109:1463–70
Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB
(2000) The design, synthesis, and evaluation of molecules that enable or
enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad
Sci USA 97:13003–8
Zeh HJ, Perry-Lalley D, Duley ME, Rosenberg SA, Yang JC (1999) High-
avidity CTLs for two self-antigens demonstrate superior in vitro and in
vivo antitumor efficacy. J Immunol 162:989–94
1812 Journal of Investigative Dermatology (2006), Volume 126
H Mitsui et al.
Polyarginine PTD-Mediated Ag Delivery to DCs
